Second-generation compound for the modulation of utrophin in the therapy of DMD
Open Access
- 1 May 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 24 (15), 4212-4224
- https://doi.org/10.1093/hmg/ddv154
Abstract
Duchenne muscular dystrophy (DMD) is a lethal, X-linked muscle-wasting disease caused by lack of the cytoskeletal protein dystrophin. There is currently no cure for DMD although various promising approaches are progressing through human clinical trials. By pharmacologically modulating the expression of the dystrophin-related protein utrophin, we have previously demonstrated in dystrophin-deficient mdx studies, daily SMT C1100 treatment significantly reduced muscle degeneration leading to improved muscle function. This manuscript describes the significant disease modifying benefits associated with daily dosing of SMT022357, a second-generation compound in this drug series with improved physicochemical properties and a more robust metabolism profile. These studies in the mdx mouse demonstrate that oral administration of SMT022357 leads to increased utrophin expression in skeletal, respiratory and cardiac muscles. Significantly, utrophin expression is localized along the length of the muscle fibre, not just at the synapse, and is fibre-type independent, suggesting that drug treatment is modulating utrophin transcription in extra-synaptic myonuclei. This results in improved sarcolemmal stability and prevents dystrophic pathology through a significant reduction of regeneration, necrosis and fibrosis. All these improvements combine to protect the mdx muscle from contraction induced damage and enhance physiological function. This detailed evaluation of the SMT C1100 drug series strongly endorses the therapeutic potential of utrophin modulation as a disease modifying therapeutic strategy for all DMD patients irrespective of their dystrophin mutation.Keywords
This publication has 87 references indexed in Scilit:
- VBP15, a novel anti‐inflammatory and membrane‐stabilizer, improves muscular dystrophy without side effectsEMBO Molecular Medicine, 2013
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- Increased Resting Intracellular Calcium Modulates NF-κB-dependent Inducible Nitric-oxide Synthase Gene Expression in Dystrophic mdx Skeletal MyotubesJournal of Biological Chemistry, 2012
- Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx miceProceedings of the National Academy of Sciences, 2010
- Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanismProceedings of the National Academy of Sciences, 2009
- Early manifestation of alteration in cardiac function in dystrophin deficient mdx mouse using 3D CMR taggingJournal of Cardiovascular Magnetic Resonance, 2009
- Modulation of utrophin A mRNA stability in fast versus slow muscles via an AU-rich element and calcineurin signalingNucleic Acids Research, 2007
- Bex1 knock out mice show altered skeletal muscle regenerationBiochemical and Biophysical Research Communications, 2007
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001